{"id":"evolocumab-amd","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PCSK9 normally binds to LDL receptors and causes their degradation, reducing the cell's ability to remove LDL cholesterol from circulation. By inhibiting PCSK9, evolocumab prevents this degradation, enabling hepatic cells to maintain higher numbers of functional LDL receptors on their surface. This results in substantially increased uptake and clearance of LDL cholesterol from the bloodstream, leading to significant reductions in LDL-C levels.","oneSentence":"Evolocumab is a PCSK9 inhibitor monoclonal antibody that binds to and inactivates PCSK9 protein, allowing LDL receptors to remain on cell surfaces and increase clearance of LDL cholesterol from the blood.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:46:39.138Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Age-related macular degeneration (AMD) — investigational indication in Phase 3"}]},"trialDetails":[{"nctId":"NCT01879319","phase":"PHASE3","title":"Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-07-11","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":164}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AMG 145","Repatha"],"phase":"phase_3","status":"active","brandName":"Evolocumab AMD","genericName":"Evolocumab AMD","companyName":"Amgen","companyId":"amgen","modality":"Biologic","firstApprovalDate":"","aiSummary":"Evolocumab is a PCSK9 inhibitor monoclonal antibody that binds to and inactivates PCSK9 protein, allowing LDL receptors to remain on cell surfaces and increase clearance of LDL cholesterol from the blood. Used for Age-related macular degeneration (AMD) — investigational indication in Phase 3.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}